Oncogenic NRAS Rapidly and Efficiently Induces CMML- and AML-like Diseases in Mice

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2006 Jun 10

PMID 16763213

Citations 50

Authors

Chaitali Parikh

Ramesh Subrahmanyam

Ruibao Ren

Affiliations

Soon will be listed here.

Abstract

Activating mutations in RAS, predominantly NRAS, are common in myeloid malignancies. Previous studies in animal models have shown that oncogenic NRAS is unable to induce myeloid malignancies effectively, and it was suggested that oncogenic NRAS might only act as a secondary mutation in leukemogenesis. In this study, we examined the leukemogenicity of NRAS using an improved mouse bone marrow transduction and transplantation model. We found that oncogenic NRAS rapidly and efficiently induced chronic myelomonocytic leukemia (CMML)- or acute myeloid leukemia (AML)- like disease in mice, indicating that mutated NRAS can function as an initiating oncogene in the induction of myeloid malignancies. In addition to CMML and AML, we found that NRAS induced mastocytosis in mice. This result indicates that activation of the RAS pathway also plays an important role in the pathogenesis of mastocytosis. The mouse model for NRAS leukemogenesis established here provides a system for further studying the molecular mechanisms in the pathogenesis of myeloid malignancies and for testing relevant therapies.

Citing Articles

A Novel Prognostic Risk-Scoring Model Based on RAS Gene-Associated Cluster in Pediatric Acute Myeloid Leukemia.

Luo C, Abudukeremu Y, Rao M, Zhou D, Fang J, Li Y Cancer Med. 2025; 14(5):e70716.

PMID: 40062727 PMC: 11891924. DOI: 10.1002/cam4.70716.

Progression and perspectives in disease modeling for Juvenile myelomonocytic leukemia.

Fu S, Guo Y, Peng Z, Zhang D, Chang Z, Xiao Y Med Oncol. 2024; 42(1):25.

PMID: 39652257 PMC: 11628578. DOI: 10.1007/s12032-024-02549-5.

Leukemic conversion involving mutations of type 1 -mutated primary myelofibrosis in a patient treated for HCV cirrhosis: a case report.

Gurban P, Mambet C, Botezatu A, Necula L, Neagu A, Matei L Front Oncol. 2023; 13:1266996.

PMID: 37841434 PMC: 10570518. DOI: 10.3389/fonc.2023.1266996.

RAB27B controls palmitoylation-dependent NRAS trafficking and signaling in myeloid leukemia.

Ren J, Xing B, Lv K, OKeefe R, Wu M, Wang R J Clin Invest. 2023; 133(12).

PMID: 37317963 PMC: 10266782. DOI: 10.1172/JCI165510.

Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.

Zavras P, Sinanidis I, Tsakiroglou P, Karantanos T Int J Mol Sci. 2023; 24(5).

PMID: 36902450 PMC: 10002503. DOI: 10.3390/ijms24055018.

References

Halene S, Wang L, Cooper R, Bockstoce D, Robbins P, Kohn D . Improved expression in hematopoietic and lymphoid cells in mice after transplantation of bone marrow transduced with a modified retroviral vector. Blood. 1999; 94(10):3349-57. PMC: 9071851. View

Zhang X, Ren R . Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood. 1998; 92(10):3829-40. View

Reuter C, Morgan M, Bergmann L . Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?. Blood. 2000; 96(5):1655-69. View

Esteban L, Vicario-Abejon C, Fernandez-Medarde A, Swaminathan N, Yienger K, Lopez E . Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol Cell Biol. 2001; 21(5):1444-52. PMC: 86690. DOI: 10.1128/MCB.21.5.1444-1452.2001. View

Vardiman J, Lee Harris N, Brunning R . The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100(7):2292-302. DOI: 10.1182/blood-2002-04-1199. View

Ren R . Dissecting the molecular mechanism of chronic myelogenous leukemia using murine models. Leuk Lymphoma. 2002; 43(8):1549-61. DOI: 10.1080/1042819021000002875. View

Midgley R, Kerr D . Ras as a target in cancer therapy. Crit Rev Oncol Hematol. 2002; 44(2):109-20. DOI: 10.1016/s1040-8428(01)00189-5. View

Thomas G . The S6 kinase signaling pathway in the control of development and growth. Biol Res. 2002; 35(2):305-13. DOI: 10.4067/s0716-97602002000200022. View

Ren R . The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model. Oncogene. 2002; 21(56):8629-42. DOI: 10.1038/sj.onc.1206090. View

10.

Stirewalt D, Appelbaum F, Willman C, Zager R, Banker D . Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression. Leuk Res. 2003; 27(2):133-45. DOI: 10.1016/s0145-2126(02)00085-1. View

11.

Ulku A, Der C . Ras signaling, deregulation of gene expression and oncogenesis. Cancer Treat Res. 2003; 115:189-208. View

12.

Hancock J . Ras proteins: different signals from different locations. Nat Rev Mol Cell Biol. 2003; 4(5):373-84. DOI: 10.1038/nrm1105. View

13.

Ren R . Modeling the dosage effect of oncogenes in leukemogenesis. Curr Opin Hematol. 2003; 11(1):25-34. DOI: 10.1097/00062752-200401000-00005. View

14.

Braun B, Tuveson D, Kong N, Le D, Kogan S, Rozmus J . Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A. 2003; 101(2):597-602. PMC: 327193. DOI: 10.1073/pnas.0307203101. View

15.

Chan I, Kutok J, Williams I, Cohen S, Kelly L, Shigematsu H . Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest. 2004; 113(4):528-38. PMC: 338267. DOI: 10.1172/JCI20476. View

16.

Rangarajan A, Hong S, Gifford A, Weinberg R . Species- and cell type-specific requirements for cellular transformation. Cancer Cell. 2004; 6(2):171-83. DOI: 10.1016/j.ccr.2004.07.009. View

17.

Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P . Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell. 1987; 49(4):465-75. DOI: 10.1016/0092-8674(87)90449-1. View

18.

Barbacid M . ras genes. Annu Rev Biochem. 1987; 56:779-827. DOI: 10.1146/annurev.bi.56.070187.004023. View

19.

Bos J . ras oncogenes in human cancer: a review. Cancer Res. 1989; 49(17):4682-9. View

20.

Haupt Y, Harris A, Adams J . Retroviral infection accelerates T lymphomagenesis in E mu-N-ras transgenic mice by activating c-myc or N-myc. Oncogene. 1992; 7(5):981-6. View